Anjali Rohatgi

449 total citations · 1 hit paper
11 papers, 309 citations indexed

About

Anjali Rohatgi is a scholar working on Oncology, Immunology and Infectious Diseases. According to data from OpenAlex, Anjali Rohatgi has authored 11 papers receiving a total of 309 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 6 papers in Immunology and 2 papers in Infectious Diseases. Recurrent topics in Anjali Rohatgi's work include Cancer Immunotherapy and Biomarkers (7 papers), CAR-T cell therapy research (6 papers) and Immunotherapy and Immune Responses (4 papers). Anjali Rohatgi is often cited by papers focused on Cancer Immunotherapy and Biomarkers (7 papers), CAR-T cell therapy research (6 papers) and Immunotherapy and Immune Responses (4 papers). Anjali Rohatgi collaborates with scholars based in United States and France. Anjali Rohatgi's co-authors include Deborah J. Lenschow, Dana L. Vanlandingham, Kristen Monte, Stephen Higgs, John M. Kirkwood, Fernando Arenzana‐Seisdedos, Scott Werneke, Alain Michault, Arnaud Fontanet and Clémentine Schilte and has published in prestigious journals such as Cell, Journal of Clinical Oncology and Journal of Virology.

In The Last Decade

Anjali Rohatgi

11 papers receiving 306 citations

Hit Papers

Blockade of LAG-3 and PD-1 leads to co-expression of cyto... 2024 2026 2025 2024 25 50 75

Peers

Anjali Rohatgi
James Testa United States
Antônio Gregorio Dias United Kingdom
Mignane Ka France
C. Melissa United States
Carole Dantin Switzerland
Anjali Rohatgi
Citations per year, relative to Anjali Rohatgi Anjali Rohatgi (= 1×) peers Annegret Bitzer

Countries citing papers authored by Anjali Rohatgi

Since Specialization
Citations

This map shows the geographic impact of Anjali Rohatgi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anjali Rohatgi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anjali Rohatgi more than expected).

Fields of papers citing papers by Anjali Rohatgi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anjali Rohatgi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anjali Rohatgi. The network helps show where Anjali Rohatgi may publish in the future.

Co-authorship network of co-authors of Anjali Rohatgi

This figure shows the co-authorship network connecting the top 25 collaborators of Anjali Rohatgi. A scholar is included among the top collaborators of Anjali Rohatgi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anjali Rohatgi. Anjali Rohatgi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

11 of 11 papers shown
1.
Ruffin, Ayana T., Sheryl Kunning, Anjali Rohatgi, et al.. (2025). Dysfunctional CD11c CD21 extrafollicular memory B cells are enriched in the periphery and tumors of patients with cancer. Science Translational Medicine. 17(786). eadh1315–eadh1315. 4 indexed citations
2.
Cillo, Anthony R., Carly Cardello, Feng Shan, et al.. (2024). Blockade of LAG-3 and PD-1 leads to co-expression of cytotoxic and exhaustion gene modules in CD8+ T cells to promote antitumor immunity. Cell. 187(16). 4373–4388.e15. 75 indexed citations breakdown →
4.
Flanagan, Mary Ellen, Pamela Samson, Saiama N. Waqar, et al.. (2022). Trends in Stage I Lung Cancer. Clinical Lung Cancer. 24(2). 114–119. 20 indexed citations
5.
Karapetyan, Lilit, Arivarasan Karunamurthy, Anthony R. Cillo, et al.. (2022). Phase II study of nivolumab (nivo) with relatlimab (rela) in patients (pts) with first-line advanced melanoma: Early on-treatment major pathologic response on biopsy.. Journal of Clinical Oncology. 40(16_suppl). 9514–9514. 1 indexed citations
6.
Rohatgi, Anjali & John M. Kirkwood. (2021). Beyond PD-1: The Next Frontier for Immunotherapy in Melanoma. Frontiers in Oncology. 11. 640314–640314. 15 indexed citations
7.
Rohatgi, Anjali & Ramaswamy Govindan. (2021). Targeting KRAS G12C mutation in lung adenocarcinoma. Lung Cancer. 165. 28–33. 10 indexed citations
8.
Rohatgi, Anjali & John M. Kirkwood. (2020). Cancer vaccine induces potent T cell responses — but is it enough?. Nature Reviews Clinical Oncology. 17(12). 721–722. 3 indexed citations
9.
10.
Rohatgi, Anjali, Joseph C. Corbo, Kristen Monte, et al.. (2013). Infection of Myofibers Contributes to Increased Pathogenicity during Infection with an Epidemic Strain of Chikungunya Virus. Journal of Virology. 88(5). 2414–2425. 26 indexed citations
11.
Werneke, Scott, Clémentine Schilte, Anjali Rohatgi, et al.. (2011). ISG15 Is Critical in the Control of Chikungunya Virus Infection Independent of UbE1L Mediated Conjugation. PLoS Pathogens. 7(10). e1002322–e1002322. 150 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026